In recent years, immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PDL1, CD274), have presented an alternative revolutionary therapeutic approach for patients with nonsquamous and squamous non-small-cell lung cancer (NSCLC)1. Here, CD274 is linked to non-small cell lung carcinoma.